Publications: Dr Manish Saxena
Bloch MJ, Kirtane AJ, Azizi M, Mahfoud F, Basile J, Daemen J, Saxena M, Thackeray L et al.
(
2024
)
.
36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO
.
Hypertension Research1
-
6
.
Greene SJ, Böhm M, Bozkurt B, Butler J, Cleland JGF, Coats AJS, Desai NR, Grobbee DE et al.
(
2024
)
.
Cardiovascular and Renal Treatment in Heart Failure Patients with Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry
.
Journal of Cardiac Failure
Unverdorben M, Colonna P, Jin J, Köhler S, Santamaria A, Saxena M, Borrow A, Chen C et al.
(
2024
)
.
Periprocedural Edoxaban Management and Clinical Outcomes in Patients Undergoing Transcatheter Cardiovascular Procedures in the EMIT-AF/VTE Program
.
Clinical and Applied Thrombosis/Hemostasis
vol.
30
,
Saxena M
(
2024
)
.
Vaccines against angiotensin receptors as a potential treatment for hypertension
.
Journal of Hypertension
vol.
42
,
(
7
)
Colonna P, Souza J, Saxena M, Vanassche T, Santamaria A, Jin J, Kohler S, Borrow A et al.
(
2024
)
.
Management of edoxaban therapy in patients undergoing emergency/urgent procedures: a subanalysis of the global, prospective, observational, multinational EMIT-AF/VTE programme
.
EP Europace
vol.
26
,
(
Supplement_1
)
Saxena M, Aswad A, Badariene J, Kazi F, Karns AD, Neutel JM, Park W, Stiglitz D et al.
(
2024
)
.
ZILEBESIRAN AS ADD-ON THERAPY IN PATIENTS WITH HYPERTENSION INADEQUATELY CONTROLLED WITH A STANDARD ANTIHYPERTENSIVE MEDICATION: EFFICACY AND SAFETY RESULTS FROM THE KARDIA-2 STUDY
.
Journal of Hypertension
vol.
42
,
(
Suppl 1
)
Hall CV, Twelves JL, Saxena M, Scapozza L, Gurry T
(
2024
)
.
Effects of a diverse prebiotic fibre supplement on HbA1c, insulin sensitivity and inflammatory biomarkers in pre-diabetes: a pilot placebo-controlled randomised clinical trial
.
British Journal Of Nutrition
vol.
132
,
(
1
)
68
-
76
.
Kandzari DE, Weber MA, Pathak A, Zidar JP, Saxena M, David SW, Schmieder RE, Janas AJ et al.
(
2024
)
.
Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial
.
Circulation
vol.
149
,
(
24
)
1875
-
1884
.
SAXENA M, Desai AS, Azizi M, Gupta A, Lee J, Stiglitz D, Makarova N, Goyal N et al.
(
2024
)
.
CONSISTENT ANTIHYPERTENSIVE EFFICACY OF THE RNA INTERFERENCE THERAPEUTIC ZILEBESIRAN: SUBGROUP RESULTS FROM THE KARDIA-1 PHASE 2 STUDY IN PATIENTS WITH HYPERTENSION
.
Journal of the American College of Cardiology
vol.
83
,
(
13
)
Bakris GL, Saxena M, Gupta A, Chalhoub F, Lee J, Stiglitz D, Makarova N, Goyal N et al.
(
2024
)
.
RNA Interference With Zilebesiran for Mild to Moderate Hypertension
.
JAMA
vol.
331
,
(
9
)
740
-
749
.
Magavern EF, Kapil V, Saxena M, Gupta A, Caulfield MJ
(
2024
)
.
Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy
.
Arteriosclerosis Thrombosis and Vascular Biology
vol.
44
,
(
4
)
784
-
793
.
Collier DJ, Taylor M, Godec T, Shiel J, James R, Chowdury Y, Ebano P, Monk V et al.
(
2024
)
.
Personalized Antihypertensive Treatment Optimization With Smartphone‐Enabled Remote Precision Dosing of Amlodipine During the COVID‐19 Pandemic (PERSONAL‐CovidBP Trial)
.
Journal of the American Heart Association
vol.
13
,
(
4
)
Bertog SC, Sharma A, Hering D, Mahfoud F, Pathak A, Schmieder RE, Sievert K, Papademetriou V et al.
(
2024
)
.
Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine™ Infusion Catheter
.
Renal Denervation
,
Springer Nature
Saxena M, Lobo MD
(
2024
)
.
What Needs to Be Shown Before Renal Denervation Can Be Used in Clinical Practice?
.
Renal Denervation
,
Springer Nature
von Heymann C, Unverdorben M, Colonna P, Santamaria A, Saxena M, Vanassche T, Köhler S, Borrow AP et al.
(
2023
)
.
Management of edoxaban therapy and clinical outcomes in patients undergoing major or nonmajor surgery: a subanalysis of the EMIT-AF/VTE study
.
Thrombosis Journal
vol.
21
,
(
1
)
Florescu S, Stanciu D, Zaharia M, Kosa A, Codreanu D, Fareed K, Kidwai A, Kaye C et al.
(
2023
)
.
Intravenous Vitamin C for Patients Hospitalized With COVID-19
.
JAMA
vol.
330
,
(
18
)
1745
-
1759
.
Azizi M, Sharp ASP, Fisher NDL, Weber MA, Lobo MD, Daemen J, Lurz P, Mahfoud F et al.
(
2023
)
.
Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program
.
Circulation
vol.
149
,
(
10
)
747
-
759
.
Azizi M, Saxena M, Wang Y, Devireddy C, Jenkins J, Fisher N, Schmieder R, Mahfoud F et al.
(
2023
)
.
TCT-398 Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: 6-Month Results Following Blinded Medication Titration in the Randomized, Sham-Controlled RADIANCE II Pivotal Trial
.
Journal of the American College of Cardiology
vol.
82
,
(
17
)
Santamaria A, Chen C, Colonna P, von Heymann C, Saxena M, Vanassche T, Jin J, Unverdorben M
(
2023
)
.
Predictive Factors and Clinical Events Associated with Edoxaban Interruption and Heparin Bridging Strategy: EMIT-AF/VTE
.
Clinical and Applied Thrombosis/Hemostasis
vol.
29
,
Lobo MD, Rull G, Saxena M, Kapil V
(
2023
)
.
Selecting patients for interventional procedures to treat hypertension
.
Blood Pressure
vol.
32
,
(
1
)
Pathak A, Rudolph UM, Saxena M, Zeller T, Müller-Ehmsen J, Lipsic E, Schmieder RE, Sievert H et al.
(
2023
)
.
Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications
.
EuroIntervention
vol.
19
,
(
7
)
602
-
611
.
Chen C, Saxena M, von Heymann C, Vanassche T, Jin J, Lersch R, Köhler S, Santamaria A et al.
(
2023
)
.
Edoxaban use in the context of dental procedures: analysis from the EMIT-AF/VTE database
.
BDJ Open
vol.
9
,
(
1
)
Kirtane AJ, Sharp ASP, Mahfoud F, Fisher NDL, Schmieder RE, Daemen J, Lobo MD, Lurz P et al.
(
2023
)
.
Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials
.
JAMA Cardiology
vol.
8
,
(
5
)
464
-
473
.
Florescu S, Stanciu D, Zaharia M, Kosa A, Codreanu D, Fareed K, Kidwai A, Kaye C et al.
(
2023
)
.
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19
.
JAMA
vol.
329
,
(
14
)
1183
-
1196
.
Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, Fisher NDL, Schmieder RE et al.
(
2023
)
.
Endovascular Ultrasound Renal Denervation to Treat Hypertension
.
JAMA
vol.
329
,
(
8
)
651
-
661
.
Wiffen L, Brown T, Maczka AB, Kapoor M, Pearce L, Chauhan M, Chauhan AJ, Saxena M et al.
(
2023
)
.
Measurement of Vital Signs by Lifelight Software in Comparison to Standard of Care Multisite Development (VISION-MD): Protocol for an Observational Study
.
JMIR Research Protocols
vol.
12
,
Florescu S, Stanciu D, Zaharia M, Kosa A, Codreanu D, Kidwai A, Masood S, Kaye C et al.
(
2023
)
.
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial
.
JAMA
vol.
329
,
(
1
)
39
-
51
.
Azizi M, Mahfoud F, Weber MA, Sharp ASP, Schmieder RE, Lurz P, Lobo MD, Fisher NDL et al.
(
2022
)
.
Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation
.
JAMA Cardiology
vol.
7
,
(
12
)
1244
-
1252
.
Heiden E, Jones T, Maczka AB, Kapoor M, Chauhan M, Wiffen L, Barham H, Holland J et al.
(
2022
)
.
Measurement of Vital Signs Using Lifelight Remote Photoplethysmography: Results of the VISION-D and VISION-V Observational Studies
.
JMIR Formative Research
vol.
6
,
(
11
)
Rader F, Kirtane AJ, Wang Y, Daemen J, Lurz P, Sayer J, Saxena M, Levy T et al.
(
2022
)
.
Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial
.
EuroIntervention
vol.
18
,
(
8
)
e677
-
e685
.
Bloch M, Kirtane A, Mahfoud F, Azizi M, Basile J, Daemen J, Saxena M, Gosse P et al.
(
2022
)
.
TCT-212 Twenty-Four Month Results in Patients With Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial
.
Journal of the American College of Cardiology
vol.
80
,
(
12
)
b85
-
b86
.
Saxena M, Von Heymann C, Santamaria A, Jin J, Chen C, Borrow A, Vanassche T, Unverdorben M et al.
(
2022
)
.
Management of edoxaban in patients undergoing multiple procedures: a subanalysis of the EMIT-AF/VTE program
.
EP Europace
vol.
24
,
(
Supplement_1
)
Florescu S, Stanciu D, Zaharia M, Kosa A, Codreanu D, Kidwai A, Masood S, Kaye C et al.
(
2022
)
.
Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19
.
JAMA
vol.
327
,
(
13
)
1247
-
1259
.
Taylor M, Godec T, Shiel J, James R, Chowdury Y, Ebano P, Monk V, Patel M et al.
(
2022
)
.
WHOSE DOSE IS IT ANYWAY? INDIVIDUAL PATIENT DOSE-RESPONSE CURVES FROM THE REMOTE-CARE PERSONAL-COVIDBP TRIAL
.
Journal of the American College of Cardiology
vol.
79
,
(
9
)
Collier D, Taylor M, Godec T, Shiel J, James R, Chowdury Y, Ebano P, Monk V et al.
(
2022
)
.
Personalized electronic record supported optimisation when alone for patients with hypertension- pilot study for remote medical management of hypertension during the Covid-19 pandemic (personal covidBP)
.
JOURNAL OF HUMAN HYPERTENSION
.
vol.
36
,
8
-
8
.
Bloch M, Kirtane A, Mahfoud F, Azizi M, Basile J, Daemen J, Saxena M, Gosse P et al.
(
2022
)
.
Twenty-Four Month Results in Patients With Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial
.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
.
vol.
80
,
B85
-
B86
.
Unverdorben M, von Heymann C, Santamaria A, Saxena M, Vanassche T, Wilkins R, Jin J, Chen C et al.
(
2021
)
.
Thromboembolic and bleeding risks in edoxaban patients with pacemaker and cardiac monitoring procedures: Outcomes of the Global EMIT program
.
Pacing and Clinical Electrophysiology
vol.
45
,
(
1
)
83
-
91
.
von Heymann C, Unverdorben M, Colonna P, Ortiz AS, Saxena M, Vanassche T, Weitz JI, Wilkins R et al.
(
2021
)
.
Management of Edoxaban Therapy in Patients Undergoing Major Surgery: A Sub-Analysis of the Prospective, Observational, Multinational Emit-AF/VTE Study
.
Blood
vol.
138
,
(
Supplement 1
)
Linschoten M, Uijl A, Schut A, Jakob CEM, Romão LR, Bell RM, McFarlane E, Stecher M et al.
(
2021
)
.
Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries
.
European Heart Journal
vol.
43
,
(
11
)
1104
-
1120
.
Writing Committee for the REMAP-CAP Investigators, Estcourt LJ, Turgeon AF, McQuilten ZK, McVerry BJ, Al-Beidh F, Annane D, Arabi YM et al.
(
2021
)
.
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial
.
JAMA
vol.
326
,
(
17
)
1690
-
1702
.
Rader F, Kirtane A, Wang Y, Daemen J, Lurz P, Sayer J, Saxena M, Levy T et al.
(
2021
)
.
TCT-369 Durability of Reduced Office-Measured Blood Pressure and Antihypertensive Medication Use After Ultrasound Renal Denervation: 24-Month Results From the RADIANCE-HTN SOLO Trial
.
Journal of the American College of Cardiology
vol.
78
,
(
19
)
Fisher NDL, Kirtane AJ, Daemen J, Rader F, Lobo MD, Saxena M, Abraham J, Schmieder RE et al.
(
2021
)
.
Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trial
.
Journal of Hypertension
vol.
40
,
(
2
)
221
-
228
.
Vanassche T, Colonna P, Santamaria A, Chen C, Von Heymann C, Jin J, Saxena M, Jiang W et al.
(
2021
)
.
Periprocedural anticoagulation management in edxoaban patients undergoing catheter-based cardiovascular procedures: analyses of the noninterventional global EMIT study
.
EP Europace
vol.
23
,
(
Supplement_3
)
Unverdorben M, Colonna P, Von Heymann C, Santamaria A, Saxena M, Vanassche T, Wilkins R, Chen C
(
2021
)
.
Periprocedural management of patients on edoxaban undergoing pacemaker and cardiac monitoring device implantation - a sub-analysis of the EMIT-AF/VTE study
.
EP Europace
vol.
23
,
(
Supplement_3
)
Saxena M, Schmieder RE, Kirtane AJ, Mahfoud F, Daemen J, Basile J, Lurz P, Gosse P et al.
(
2021
)
.
Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study
.
Journal of Human Hypertension
vol.
36
,
(
7
)
629
-
639
.
Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, Rump LC, Persu A et al.
(
2021
)
.
Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial
.
The Lancet
vol.
397
,
(
10293
)
2476
-
2486
.
Saxena M, Kermali M, Balawon A, Pheby J, Benu E, Piniera B, Low D, Mathur A et al.
(
2021
)
.
COLLATERAL BENEFITS OF PARTICIPATION IN CLINICAL RESEARCH: INSIGHTS FROM A RESISTANT HYPERTENSION TRIAL SCREEN OUT POPULATION
.
Journal of Hypertension
.
vol.
39
,
Unverdorben M, von Heymann C, Santamaria A, Saxena M, Vanassche T, Jin J, Laeis P, Wilkins R et al.
(
2021
)
.
Correction to: Elderly patients with atrial fibrillation in routine clinical practice: peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study
.
BMC Cardiovascular Disorders
vol.
21
,
(
1
)
Rader F, Kirtane A, Wang Y, Daemen J, Lurz P, Sayer J, Saxena M, Levy T et al.
(
2021
)
.
Durability of Reduced Office-Measured Blood Pressure and Antihypertensive Medication Use After Ultrasound Renal Denervation: 24-Month Results From the RADIANCE-HTN SOLO Trial
.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
.
vol.
78
,
B152
-
B152
.
Maniero C, Julu P, Shah M, Wolff C, Kapil V, Rull G, Gupta A, Saxena M et al.
(
2021
)
.
Dysregulation of central respiratory modulation of cardiac vagal tone is a novel, early sign of dysautonomia in patients with α-synucleinopathies
.
JOURNAL OF HUMAN HYPERTENSION
.
vol.
35
,
16
-
16
.
Gosse P, Cremer A, Kirtane AJ, Lobo MD, Saxena M, Daemen J, Wang Y, Stegbauer J et al.
(
2020
)
.
Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation
.
Hypertension
vol.
77
,
(
2
)
529
-
536
.
Azizi M, Daemen J, Lobo MD, Mahfoud F, Sharp ASP, Schmieder RE, Wang Y, Saxena M et al.
(
2020
)
.
12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation
.
JACC Cardiovascular Interventions
vol.
13
,
(
24
)
2922
-
2933
.
Unverdorben M, von Heymann C, Santamaria A, Saxena M, Vanassche T, Jin J, Laeis P, Wilkins R et al.
(
2020
)
.
Elderly patients with atrial fibrillation in routine clinical practice—peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study
.
BMC Cardiovascular Disorders
vol.
20
,
(
1
)
Feyz L, Wang Y, Pathak A, Saxena M, Mahfoud F, Sanghvi K, Peterson R, Kirtane AJ et al.
(
2020
)
.
Using social media to recruit study participants for a randomized trial for hypertension
.
European Heart Journal - Digital Health
vol.
1
,
(
1
)
71
-
74
.
Santamaria A, Colonna P, von Heymann C, Saxena M, Vanassche T, Jin J, Wilkins R, Chen C et al.
(
2020
)
.
Periprocedural Interruption of Edoxaban in Real World Setting: Results from the Emit AF/VTE Study
.
Blood
vol.
136
,
(
Supplement 1
)
13
-
14
.
Bertog S, Sharma A, Mahfoud F, Pathak A, Schmieder RE, Sievert K, Papademetriou V, Weber MA et al.
(
2020
)
.
Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine™ Infusion Catheter
.
Cardiovascular Revascularization Medicine
vol.
24
,
77
-
86
.
Colonna P, von Heymann C, Santamaria A, Saxena M, Vanassche T, Wolpert D, Laeis P, Wilkins R et al.
(
2020
)
.
Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT‐AF/VTE study
.
Clinical Cardiology
vol.
43
,
(
7
)
769
-
780
.
Saxena M, Kermali M, Balawon A, Pheby J, Benu E, Piniera B, Low D, Mathur A et al.
(
2020
)
.
Collateral benefits of participation in clinical research: insights from a resistant hypertension trial screen out population
.
JOURNAL OF HUMAN HYPERTENSION
.
vol.
34
,
Lobo MD, Sharp ASP, Kapil V, Davies J, de Belder MA, Cleveland T, Bent C, Chapman N et al.
(
2019
)
.
Joint UK societies’ 2019 consensus statement on renal denervation
.
Heart
vol.
105
,
(
19
)
Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Lobo MD, Sharp ASP, Bloch MJ et al.
(
2019
)
.
Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial
.
Circulation
vol.
139
,
(
22
)
2542
-
2553
.
Azizi M, Schmieder R, Mahfoud F, Weber M, Daemen J, Lobo M, Sharp A, Basile J et al.
(
2019
)
.
TREATMENT-BLINDED MEDICATION TITRATION FOR HYPERTENSION CONTROL FOLLOWING RANDOMIZATION TO ENDOVASCULAR ULTRASOUND RENAL DENERVATION OR A SHAM PROCEDURE
.
Journal of the American College of Cardiology
vol.
73
,
(
9
)
McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE et al.
(
2019
)
.
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
.
Circulation
vol.
139
,
(
3
)
351
-
361
.
Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M et al.
(
2019
)
.
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
.
JAMA
vol.
321
,
(
1
)
69
-
79
.
Sharp ASP, Saxena M, Lobo MD
(
2018
)
.
Renal artery sympathetic denervation: Back on track!
.
European Heart Journal
vol.
39
,
(
46
)
4056
-
4057
.
Saxena M, Shour T, Shah M, Wolff CB, Julu POO, Kapil V, Collier DJ, Ng FL et al.
(
2018
)
.
Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success
.
J Am Heart Assoc
vol.
7
,
(
12
)
Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK et al.
(
2018
)
.
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
.
Lancet Diabetes Endocrinol
vol.
6
,
(
6
)
464
-
475
.
Saxena M, Sobotka P, Balmforth P, Mathur A, Jain A, Rensing B, Lobo M
(
2018
)
.
IMMEDIATE, SIGNIFICANT DECLINE IN CENTRAL AND PERIPHERAL BLOOD PRESSURE WITH CENTRAL ARTERIAL VENOUS ANASTOMOSIS
.
Journal of Hypertension
.
vol.
36
,
BROWN MJ
(
2018
)
.
Investigation of the endocrine and haemodynamic changes in resistant hypertension, and its response to spironolactone or amiloride: the PATHWAY-2 mechanisms study
.
Lancet Diabetes and Endocrinology
vol.
6
,
(
6
)
464
-
475
.
Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, Basile J, Kirtane AJ et al.
(
2018
)
.
Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial
.
The Lancet
vol.
391
,
(
10137
)
2335
-
2345
.
Mukhtar O, Cheriyan J, Cockcroft JR, Collier D, Coulson JM, Dasgupta I, Faconti L, Glover M et al.
(
2018
)
.
A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program—AIM-HY INFORM trial
.
American Heart Journal
vol.
204
,
102
-
108
.
Schmieder RE, Ott C, Toennes SW, Bramlage P, Gertner M, Dawood O, Baumgart P, O'Brien B et al.
(
2018
)
.
Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension – WAVE IV
.
Journal of Hypertension
.
vol.
36
,
680
-
689
.
MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK, Ford I, Sever P et al.
(
2017
)
.
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial
.
J Am Heart Assoc
vol.
6
,
(
11
)
Lobo MD, Ott C, Sobotka PA, Saxena M, Stanton A, Cockcroft JR, Sulke N, Dolan E et al.
(
2017
)
.
Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension
.
Hypertension
vol.
70
,
(
6
)
1099
-
1105
.
Schmieder RE, Ott C, Toennes S, Gertner M, Dawood O, Saxena M, O’Brien B, Lobo M
(
2017
)
.
[LB.01.02] PHASE II RANDOMIZED SHAM-CONTROLLED STUDY OF RENAL DENERVATION FOR SUBJECTS WITH UNCONTROLLED HYPERTENSION – WAVE IV
.
Journal of Hypertension
.
vol.
35
,
Saxena M, Shour T, Shah M, Wolff C, Collier DJ, Kapil V, Balawon A, Pheby JM et al.
(
2017
)
.
[LB.03.06] ATTENUATION OF SPLANCHNIC AUTOTRANSFUSION FOLLOWING NON-INVASIVE ULTRASOUND RENAL DENERVATION
.
Journal of Hypertension
.
vol.
35
,
e77
-
e78
.
Ormiston J, Neuzil P, O’brien B, Saxena M, Schmieder RE, Gertner M, Dawood O, Lobo MD
(
2017
)
.
[PP.15.25] REDO RENAL DENERVATION WITH NON-INVASIVE THERAPEUTIC ULTRASOUND
.
Journal of Hypertension
.
vol.
35
,
Lobo M, Montarello J, Saxena M, Jain A, Walters D, Pincus M, Worthley S
(
2017
)
.
[PP.15.26] RENAL DENERVATION USING THE ENLIGHTN RENAL DENERVATION SYSTEM IN ALTERNATIVE HYPERTENSIVE POPULATIONS
.
Journal of Hypertension
.
vol.
35
,
SAXENA M, Shour T, Sobotka P, Jain A, Collier DJ, Hamshere S, Mathur A, Knight C et al.
(
2017
)
.
[PP.24.26] ANTIHYPERTENSIVE EFFECTS OF A CENTRAL ARTERIOVENOUS ANASTOMOSIS ARE MEDIATED THROUGH PROFOUND REDUCTION IN SYSTEMIC VASCULAR RESISTANCE
.
Journal of Hypertension
.
vol.
35
,
e293
-
e294
.
Saxena M, Shour T, Shah M, Wolff C, Collier DJ, Kapil V, Balawon A, Pheby JM et al.
(
2017
)
.
Attenuation of splanchnic autotransfusion following non-invasive ultrasound renal denervation: a novel marker of procedural success
.
JOURNAL OF HUMAN HYPERTENSION
.
vol.
31
,
679
-
680
.
Ott C, Lobo MD, Sobotka PA, Mahfoud F, Stanton A, Cockcroft J, Sulke N, Dolan E et al.
(
2016
)
.
Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension
.
J Am Heart Assoc
vol.
5
,
(
12
)
Floyd CN, Adeel MY, Wolff CB, Julu P, Shah M, Collier DJ, Saxena M, Brier T et al.
(
2016
)
.
First-in-man treatment of severe blood pressure variability with baroreflex activation therapy
.
International Journal of Cardiology
vol.
220
,
Article
C
,
577
-
579
.
Lobo MD, Montarello J, Saxena M, Jain A, Walters D, Pincus M, Tsioufis C, Papademetriou V et al.
(
2016
)
.
[OP.4C.04] SAFETY AND PERFORMANCE OF THE ENLIGHTN RENAL DENERVATION SYSTEM IN PATIENTS WITH DRUG-RESISTANT HYPERTENSION
.
Journal of Hypertension
vol.
34
,
(
&NA;
)
Lobo MD, Adeel MY, Wolff CB, Julu PO, Shah M, Collier DM, Saxena M, Floyd C et al.
(
2016
)
.
[OP.8D.02] FIRST IN MAN TREATMENT OF SEVERE BP VARIABILITY WITH BAROREFLEX ACTIVATION THERAPY
.
J Hypertens
vol.
34 Suppl 2
,
e105
-
e105
.
Lobo M, Saxena M, Sobotka PA, Ott C, Dolan E, Foran J, Furniss SS, Cockcroft J et al.
(
2016
)
.
[OP.LB.02.04] CENTRAL ILIAC ARTERIOVENOUS ANASTOMOSIS FOR UNCONTROLLED HYPERTENSION
.
Journal of Hypertension
vol.
34
,
(
&NA;
)
e78
-
e79
.
Lobo MD, Montarello J, Saxena M, Jain AK, Walters D, Pincus M, Worthley SG
(
2016
)
.
[PP.26.11] RENAL DENERVATION USING THE ENLIGHTN RENAL DENERVATION SYSTEM IN ALTERNATIVE HYPERTENSIVE POPULATIONS
.
Journal of Hypertension
.
vol.
34
,
Wolff C, Julu PO, Collier DJ, Saxena M, Kapil V, Shah M, Eftychiou S, Mills E et al.
(
2016
)
.
[PP.38.09] EFFECTS OF MILD DYNAMIC EXERCISE ON CIRCULATORY AND AUTONOMIC FUNCTION IN HEALTHY VOLUNTEERS
.
Journal of Hypertension
.
vol.
34
,
e351
-
e352
.
Saxena M, Sobotka PA, Hamshere SM, Jain A, Mathur A, Knight C, Collier DJ, Lobo MD
(
2016
)
.
Antihypertensive effects of a central arteriovenous anastomosis are mediated through profound reduction in systemic vascular resistance
.
Circulation: Cardiovascular Interventions
vol.
9
,
(
8
)
Ng FL, Saxena M, Mahfoud F, Pathak A, Lobo MD
(
2016
)
.
Device-based Therapy for Hypertension
.
Curr Hypertens Rep
vol.
18
,
(
8
)
61
-
61
.
De Jager RL, Sanders MF, Bots ML, Lobo MD, Ewen S, Beeftink MMA, Böhm M, Daemen J et al.
(
2016
)
.
Renal denervation in hypertensive patients not on blood pressure lowering drugs
.
Clinical Research in Cardiology
vol.
105
,
(
9
)
755
-
762
.
Saxena M, Antoniou S, Hamedi N, Robinson P, Singh H, Mukhtar O, Kapil V, Lobo MD
(
2016
)
.
Multiple drug-intolerant hypertension: a case series utilising a novel-treatment algorithm
.
British Journal of General Practice
vol.
66
,
(
645
)
e285
-
e287
.
Burchell AE, Chan K, Ratcliffe LEK, Hart EC, Saxena M, Collier DJ, Jain AK, Mathur A et al.
(
2016
)
.
Controversies Surrounding Renal Denervation: Lessons Learned From Real‐World Experience in Two United Kingdom Centers
.
Journal of Clinical Hypertension
vol.
18
,
(
6
)
585
-
592
.
Antoniou S, Saxena M, Hamedi N, de Cates C, Moghul S, Lidder S, Kapil V, Lobo MD
(
2016
)
.
Management of Hypertensive Patients With Multiple Drug Intolerances: A Single-Center Experience of a Novel Treatment Algorithm
.
Journal of Clinical Hypertension
vol.
18
,
(
2
)
129
-
138
.
Wolff CB, Collier DJ, Shah M, Saxena M, Brier TJ, Kapil V, Green D, Lobo M
(
2016
)
.
A Discussion on the Regulation of Blood Flow and Pressure
.
Advances in Experimental Medicine and Biology
vol.
876
,
129
-
135
.
Antoniou S, Saxena M, Hamedi N, de Cates C, Moghul S, Lidder S, Kapil V, Lobo MD
(
2016
)
.
Management of Hypertensive Patients With Multiple Drug Intolerances: A Single-Center Experience of a Novel Treatment Algorithm
.
JOURNAL OF CLINICAL HYPERTENSION
vol.
18
,
(
2
)
129
-
138
.
Lobo M, Montarello J, Saxena M, Jain A, Walters D, Pincus MW, Worthley SG
(
2015
)
.
TCT-771 Safety and Performance of the EnligHTN Renal Denervation System in Patients with Uncontrolled Hypertension and Chronic Kidney Disease: 12 Month Results from the EnligHTN II Study
.
Journal of the American College of Cardiology
.
vol.
66
,
b313
-
b314
.
Worthley SG, Montarello J, Saxena M, Jain A, Walters D, Pincus MW, Tsioufis KP, Papademetriou V et al.
(
2015
)
.
TCT-774 Safety and Performance of the EnligHTN™ Renal Denervation System in Patients with Drug-resistant Hypertension: Pooled analyses from the EnligHTN I, II and III trials
.
Journal of the American College of Cardiology
.
vol.
66
,
Lobo M, Montarello J, Saxena M, Jain A, Walters D, Pincus MW, Worthley SG
(
2015
)
.
TCT-85 Safety and Performance of the EnligHTN Renal Denervation System in Patients with Severe Uncontrolled Hypertension: 12 Month Results from the EnligHTN II Study
.
Journal of the American College of Cardiology
.
vol.
66
,
b39
-
b40
.
Kapil V, Sobotka PA, Saxena M, Mathur A, Knight C, Dolan E, Stanton A, Lobo MD
(
2015
)
.
Central Iliac Arteriovenous Anastomosis for Hypertension: Targeting Mechanical Aspects of the Circulation
.
Current Hypertension Reports
vol.
17
,
(
9
)
Lobo M, Saxena M, Jain AJ, Walters D, Pincus M, Montarello J, Worthley SG
(
2015
)
.
4A.09
.
Journal of Hypertension
.
vol.
33
,
Saxena M, Collier D, Jain A, Knight C, Mathur A, Sobotka P, Lobo M
(
2015
)
.
8C.09
.
Journal of Hypertension
.
vol.
33
,
Antoniou S, Saxena M, Hamedi N, De Cates C, Moghul S, Lidder S, Lobo M, Kapil V
(
2015
)
.
PP.21.35
.
Journal of Hypertension
.
vol.
33
,
Worthley S, Montarello J, Saxena M, Jain A, Walters D, Pincus M, Tsioufis C, Papademetriou V et al.
(
2015
)
.
PP.26.05
.
Journal of Hypertension
vol.
33
,
(
&NA;
)
Lobo M, Saxena M, Jain A, Walters D, Pincus M, Montarello J, Worthley S
(
2015
)
.
PP.26.22
.
Journal of Hypertension
vol.
33
,
(
&NA;
)
Lobo M, Saxena M, Jain A, Walters D, Pincus M, Montarello J, Worthley S
(
2015
)
.
PP.26.23
.
Journal of Hypertension
vol.
33
,
(
&NA;
)
e363
-
e364
.
Antoniou S, Hamedi N, Lidder S, Saxena M, Brier T, Robinson P, Kapil V, Lobo M
(
2015
)
.
CP-081 Management of uncontrolled blood pressure in patients with multiple drug intolerance referred to a specialist hypertension clinic
.
European Journal of Hospital Pharmacy
vol.
22
,
(
Suppl 1
)
Saxena M, Collier D, Jain A, Mathur A, Knight C, Sobotka P, Lobo M
(
2015
)
.
A central iliac arteriovenous anastomosis results in durable and substantial blood pressure reduction in a woman with uncontrolled hypertension and multiple antihypertensive drug intolerances
.
JOURNAL OF HUMAN HYPERTENSION
vol.
29
,
(
10
)
631
-
632
.
Burchell AE, Chan K, Hart EC, Saxena M, Jain AK, Collier DJ, Paton JFR, Nightingale AK et al.
(
2015
)
.
Challenges facing renal denervation: insight from real world experience at two UK centres
.
EUROPEAN HEART JOURNAL
.
vol.
36
,
505
-
506
.
Lobo M, Saxena M, Jain A, Walters D, Pincus M, Montarello J, Worthley S
(
2015
)
.
SAFETY AND PERFORMANCE OF THE ENLIGHTN RENAL DENERVATION SYSTEM IN PATIENTS WITH MODERATE UNCONTROLLED HYPERTENSION: 12 MONTH RESULTS FROM THE ENLIGHTN II STUDY
.
JOURNAL OF HYPERTENSION
.
vol.
33
,
E363
-
E364
.
Lobo M, Saxena M, Jain A, Walters D, Pincus M, Montarello J, Worthley S
(
2015
)
.
SAFETY AND PERFORMANCE OF THE ENLIGHTN RENAL DENERVATION SYSTEM IN PATIENTS WITH UNCONTROLLED HYPERTENSION AND CHRONIC KIDNEY DISEASE: 12 MONTH RESULTS FROM THE ENLIGHTN II STUDY
.
JOURNAL OF HYPERTENSION
.
vol.
33
,
E363
-
E363
.
Worthley S, Montarello J, Saxena M, Jain A, Walters D, Pincus M, Tsioufis C, Papademetriou V et al.
(
2015
)
.
SAFETY AND PERFORMANCE OF THE ENLIGHTN™ RENAL DENERVATION SYSTEM IN PATIENTS WITH DRUG-RESISTANT HYPERTENSION: POOLED ANALYSES FROM THE ENLIGHTN I, II AND III TRIALS
.
JOURNAL OF HYPERTENSION
.
vol.
33
,
E359
-
E359
.
Lobo MD, Montarello J, Saxena M, Jain AK, Walters D, Pincus M, Worthley SG
(
2015
)
.
Safety and performance of the EnligHTN renal denervation system in patients with severe uncontrolled hypertension: 12 month results from the EnligHTN II Study
.
JOURNAL OF HUMAN HYPERTENSION
vol.
29
,
(
10
)
631
-
631
.
Saxena M, Antoniou S, Hamedi N, Chowdhury R, Lidder S, Brier T, Robinson P, Kapil V et al.
(
2014
)
.
Anti-hypertensive medicine intolerance - an overlooked and important cause of failed compliance
.
JOURNAL OF HUMAN HYPERTENSION
vol.
28
,
(
10
)
633
-
633
.
Saxena M, Jain A, Mathur A, Knight C, Caulfield M, Collier D, Lobo M
(
2014
)
.
Early reduction in blood pressure and heart rate variability following multielectrode radio-frequency renal denervation in medicines intolerant patients
.
JOURNAL OF HUMAN HYPERTENSION
.
vol.
28
,
647
-
647
.
Burchell A, Chan K, Ratcliffe L, Hart E, Saxena M, Collier D, Jain A, Mathur A et al.
(
2014
)
.
Highly variable response to renal denervation for resistant hypertension - real world experience from 2 UK centres
.
JOURNAL OF HUMAN HYPERTENSION
.
vol.
28
,
645
-
646
.
Antoniou S, Hamedi N, Choudhury R, Lidder S, Saxena M, Brier T, Robinson P, Kapil V et al.
(
2014
)
.
Management of uncontrolled blood pressure in patients referred to a specialist hypertension clinic with multiple medicines intolerance
.
JOURNAL OF HUMAN HYPERTENSION
vol.
28
,
(
10
)
645
-
645
.
Saxena M, Collier D, Caulfield M, Lobo M
(
2012
)
.
Patients with resistant hypertension warrant a trial of salt restriction before and after renal denervation (RD)
.
JOURNAL OF HUMAN HYPERTENSION
vol.
26
,
(
10
)
619
-
619
.
Chan K, Ng FL, Saxena M, Collier D, Matson M, Jain A, Caulfield M, Lobo M
(
2012
)
.
Renal denervation in resistant hypertension-a prospective case series
.
JOURNAL OF HUMAN HYPERTENSION
vol.
26
,
(
10
)
631
-
631
.
Collier DJ, Robson J, Scott R, Will CM, Eldridge SE, Griffiths CJ, Badrick E, Saxena M et al.
(
2010
)
.
HiLo: a health services intervention study: methods and interim results on the first 2000 patients at 1 year
.
J HUM HYPERTENS
vol.
24
,
(
10
)
708
-
709
.